Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Hsp90 is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Esanex Inc.
• Collaborator: Serenex, Inc.

Criteria

Inclusion Criteria:

• >18 years old

• Karnofsky performance status > 60

• confirmed hematological malignancy

• refractory to available therapy or for which no therapy is available

• adequate hepatic, renal and hematological function

Exclusion Criteria:

• CNS malignancy

• at risk for prolonged QT interval

• significant GI/liver disease

• other serious concurrent illness or medical condition